There are currently 974 clinical trials in Ann Arbor, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Michigan, University of Michigan Comprehensive Cancer Center, University of Michigan Health System and C.S. Mott Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Symphony IL-6 Study in Patients at Risk of Severe Sepsis
NCT05665153
Recruiting
Symphony IL-6 is a device that quantitates human IL-6 by fluorescence enzyme immunoassay (FEIA) from whole-blood specimens. Use of Symphony IL- 6 removes the need for plasma separation before testing. Symphony IL-6 comprises two components, the Symphony Fluorescence Immunoanalyzer and the Symphony IL-6 Cartridge. Whole blood is added to the cartridge and then up to six cartridges can be inserted into the immunoanalyzer. After 20 minutes a readout and printout are given with a quantitative IL-6 c... Read More
Gender:
All
Ages:
22 years and above
Trial Updated:
09/05/2023
Locations: University of Michigan Medical Center, Ann Arbor, Michigan
Conditions: Severe Sepsis
Register for Updates
A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
NCT05181137
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/01/2023
Locations: Michigan Medical, Ann Arbor, Michigan
Conditions: Ulcerative Colitis
Register for Updates
Total Shoulder Arthroplasty Multi-Center Registry
NCT03511586
Recruiting
The objective of the study is a multi-center prospective registry to collect clinical outcomes of anatomic and reverse total shoulder arthroplasty.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
07/27/2023
Locations: The University of Michigan, Ann Arbor, Michigan
Conditions: Shoulder Arthroplasty
Register for Updates
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
NCT05708950
Recruiting
The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors. The main questions this study aims to answer are: What is the safety of KVA12123 when administered alone and in combination with pembrolizumab to advanced cancer patients? What is an appropriate dose of KVA12123 to administer alone and in combination with pembrolizumab to advanced cancer patients in future clinical trials? Participants in t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/11/2023
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
Register for Updates
Terumo Aortic Global Endovascular Registry
NCT04246463
Recruiting
Multi-arm, multi-center, open label, prospective observational registry designed to obtain safety and performance data on the use of CE marked and custom Terumo Aortic endovascular grafts.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2023
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
Register for Updates
TRIAD Appendicitis Decision-making Surveys
NCT05887414
Recruiting
While appendectomy has been the main treatment of appendicitis for over 100 years, recent European studies found that, at least among highly selected patients, antibiotics alone can be an effective alternative. Surgeons and patients alike have a difficult time deciding if surgery or antibiotics are the best choice to treat appendicitis. The goal of the TRIAD is to evaluate the patients who are a part of the TRIAD implementation program and assess satisfaction and decisional regret for patients w... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2023
Locations: Michigan Medicine- University of Michigan, Ann Arbor, Michigan
Conditions: Appendicitis
Register for Updates
GCC19CART for Patients With Metastatic Colorectal Cancer
NCT05319314
Recruiting
Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/02/2023
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Colorectal Cancer
Register for Updates
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
NCT01060371
Recruiting
Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance, poor coordination, and speech difficulties. There are different kinds of SCA and this study will focus on types 1, 2,3, and 6 (SCA 1, SCA 2, SCA 3 , also known as Machado-Joseph disease and SCA 6). The diseases are rare, slowly progressive, cause increasingly severe neurological difficulties and are variable across and within genotypes. The purpose of this research study is to bring together a group of experts... Read More
Gender:
All
Ages:
6 years and above
Trial Updated:
05/30/2023
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6
Register for Updates
International CIPN Assessment and Validation Study
NCT04633655
Recruiting
This is an observational study of chemotherapy-induced peripheral neurotoxicity (CIPN) patients to be investigated prospectively in order to assess responsiveness of a set of outcome measures in an international multi-center study.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2023
Locations: University of Michigan School of Nursing, Ann Arbor, Michigan
Conditions: Chemotherapy-induced Peripheral Neuropathy, Quality of Life
Register for Updates
A Clinical Trial Evaluating Diets for IBS
NCT05831306
Recruiting
Diet and lifestyle changes are the recommended first line treatments for symptom relief in irritable bowel syndrome (IBS). Currently the only diet that is widely recommended and for which there is good evidence of efficacy in IBS is one low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (low-FODMAP). While effective, the Low-FODMAP diet is burdensome and costly to patients and in clinical practice adherence to FODMAP restriction is less than optimal. Further, patien... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/27/2023
Locations: University of Michigan - Ann Arbor, Ann Arbor, Michigan
Conditions: Irritable Bowel Syndrome
Register for Updates
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT03412643
Recruiting
This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: St. Joseph Mercy Hospital, Ann Arbor, Michigan
Conditions: HER2-negative Breast Cancer
Register for Updates
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
NCT03787602
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Merkel Cell Carcinoma
Register for Updates